US Bioservices Announces Wins in Three Strategic Areas

February 7, 2018
Pharmaceutical Executive

US Bioservices, an independent pharmacy and a part of AmerisourceBergen, announced that 2017 was a record-breaking year for new business wins in three strategic areas-oncology, rare and orphan, and specialty infusion. US Bioservices received access to 28 new products in 2017, including 10 oncology products and three rare and orphan therapies.

US Bioservices’ portfolio offers:

  • Specialty Infusion: US Bioservices has more than 25 years of experience providing specialty infusion therapies, including IV drugs, and self-administered infusion and injection medications, to patients nationwide. US Bioservices offers personalized clinical support, including self-infusion training, in-home infusion nursing services and 24/7 access to clinical support.

  • Oncology: With more than 80 members, US Bioservices’ Oncology Patient Support Team provides clinical care that is specific to the patient’s needs, conditions, and therapies.

  • Rare & Orphan: US Bioservices’ depth of experience supporting rare and orphan programs, combined with AmerisourceBergen’s Signature® commercialization solutions, provide a range of program and partnership options that can be tailored to maximize results.

Through comprehensive technology systems, US Bioservices’ manufacturer partners get a transparent view into the therapy experience.

US Bioservices leverages resources provided by AmerisourceBergen companies, including Lash Group for patient support services; ION Solutions and Oncology Support for their connections to community oncology providers, and ICS and ASD Healthcare for rare and orphan logistics and distribution.